Instrument Inactif

Communiqués Bio-Path Holdings Inc Nasdaq

Actions

US09057N2018

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Bio-Path Holdings Provides Clinical Update and Expansion Plans	08/07	AQ
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress	14/06	AQ
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	05/06	AQ
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24	04/06	NE
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	04/06	AQ
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting	03/06	AQ
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress	24/05	AQ
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting	23/05	AQ
Bio-Path: Q1 Earnings Snapshot	15/05	AQ
Bio-Path Holdings Reports First Quarter 2024 Financial Results	15/05	AQ
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024	08/05	AQ
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	22/04	AQ
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-theMarket Under Nasdaq Rules	19/04	AQ
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	18/04	AQ
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients	18/04	AQ
Bio-Path Holdings Expands Global Patent Portfolio	15/04	AQ
Bio-Path Holdings Provides 2024 Clinical and Operational Update	02/04	AQ
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23	27/03	NE
Bio Path : Failure to Satisfy Listing Rule - Form 8-K	13/03	PU
Bio-Path Holdings Reports Full Year 2023 Financial Results	08/03	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Bio-Path Holdings Inc Nasdaq

Actions

US09057N2018

Communiqués

Filtres